Lymphoscintigraphy Directed Elective Neck Radiation for p16+ Favorable Risk Oropharynx Cancer
NCT05800574
Recruiting
This is a prospective, phase II, stratified single arm investigation for favorable prognosis in p16+ oropharynx cancer patients with either node negative or malignant neck adenopathy with lymphoscintigraphy mapping confined to the ipsilateral neck.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/20/2024
Locations: Fox Chase Cancer Center, Philadelphia, Pennsylvania
Conditions: Oropharynx Cancer
Register for Updates
Risk Enabled Therapy After Initiating Neoadjuvant Chemotherapy for Bladder Cancer (RETAIN)
NCT02710734
Active Not Recruiting
The aim of this study is to evaluate a risk-adapted approach to the treatment of muscle invasive bladder cancer. Each baseline transuretheral resection of bladder tumor (TURBT) sample will be sequenced while proceeding with neoadjuvant accelerated methotrexate, vinblastine, doxorubicin, and cisplatin (AMVAC) chemotherapy. Based on the mutational profile and the post AMVAC TURBT findings, patients will be treated with active surveillance (experimental arm), or standard of care intravesicle therap... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/20/2024
Locations: Washington Cancer Institute at MedStar Washington Hospital Center, Washington, District of Columbia +3 locations
Conditions: Urothelial Carcinoma of the Bladder
Register for Updates
Chemotherapy Before Surgery and Radiation Therapy or Surgery and Radiation Therapy Alone in Treating Patients With Nasal and Paranasal Sinus Cancer That Can Be Removed by Surgery
NCT03493425
Recruiting
This randomized phase II trial studies how well chemotherapy before surgery and radiation therapy works compared to surgery and radiation therapy alone in treating patients with nasal and paranasal sinus cancer that can be removed by surgery. Drugs used in chemotherapy, such as docetaxel, cisplatin, and carboplatin work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high-... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/19/2024
Locations: University of Arizona Cancer Center-Orange Grove Campus, Tucson, Arizona +139 locations
Conditions: Stage III Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma AJCC v6 and v7, Stage IVA Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma AJCC v7
Register for Updates
Perioperative Enfortumab Vedotin (EV) Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Chemotherapy for Cisplatin-Eligible Muscle Invasive Bladder Cancer (MIBC) (MK-3475-B15/ KEYNOTE-B15 / EV-304)
NCT04700124
Active Not Recruiting
The purpose of this study is to assess the antitumor efficacy and safety of perioperative enfortumab vedotin (EV) plus pembrolizumab and radical cystectomy (RC) + pelvic lymph node dissection (PLND) compared with the current standard of care (neoadjuvant chemotherapy \[gemcitabine plus cisplatin\] and RC + PLND) for participants with MIBC who are cisplatin-eligible. The primary hypothesis is perioperative EV and pembrolizumab and RC + PLND (Arm A) will achieve superior event free survival (EFS)... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/19/2024
Locations: Mayo Clinic in Arizona - Phoenix ( Site 0043), Phoenix, Arizona +187 locations
Conditions: Bladder Cancer
Register for Updates
Durvalumab Followed by Chemoradiation and Consolidation Durvalumab for Stage III Non-small Cell Lung Cancer
NCT04364048
Terminated
Single arm study of induction durvalumab (1500 mg IV) for 1 cycle (every 4 weeks), administered prior to starting concurrent definitive chemoradiation, followed by consolidation durvalumab (1500 mg IV every 4 weeks) for up to 12 cycles. The study will include an initial safety run-in portion. Patients in the safety run-in will be monitored through completion of induction durvalumab, chemoradiation, and 2 cycles of consolidation durvalumab for assessment of safety prior to completion of enrollme... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/18/2024
Locations: Rush University Medical Center, Chicago, Illinois +4 locations
Conditions: Lung Cancer, Non-small Cell Carcinoma
Register for Updates
A Study of Gemcitabine, Nab-paclitaxel, Capecitabine, Cisplatin, and Irinotecan in Metastatic Pancreatic Cancer
NCT03535727
Completed
The purpose of this study is to evaluate the clinical activity of gemcitabine, nab-paclitaxel, capecitabine, cisplatin, and irinotecan (GAX-CI) in patients with metastatic pancreatic cancer.
Gender:
ALL
Ages:
Between 18 years and 76 years
Trial Updated:
12/13/2024
Locations: Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland
Conditions: Adenocarcinoma, Pancreatic Neoplasms, Neoplasm, Glandular, Neoplasms, Neoplasms Pancreatic, Digestive System Neoplasm, Endocrine Gland Neoplasms, Digestive System Disease, Pancreatic Diseases, Endocrine System Diseases
Register for Updates
Comparing Photon Therapy To Proton Therapy To Treat Patients With Lung Cancer
NCT01993810
Active Not Recruiting
This randomized phase III trial studies proton chemoradiotherapy to see how well it works compared to photon chemoradiotherapy in treating patients with stage II-IIIB non-small cell lung cancer that cannot be removed by surgery. Specialized radiation therapy that delivers a high dose of radiation directly to the tumor, such as photon or proton beam radiation therapy, may kill more tumor cells and cause less damage to normal tissue. Drugs used in chemotherapy, such as paclitaxel, carboplatin, eto... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/13/2024
Locations: University of Florida Health Science Center - Jacksonville, Jacksonville, Florida +29 locations
Conditions: Stage II Non-Small Cell Lung Cancer AJCC v7, Stage IIA Non-Small Cell Lung Carcinoma AJCC v7, Stage IIB Non-Small Cell Lung Carcinoma AJCC v7, Stage III Non-Small Cell Lung Cancer AJCC v7, Stage IIIA Non-Small Cell Lung Cancer AJCC v7, Stage IIIB Non-Small Cell Lung Cancer AJCC v7
Register for Updates
De-intensification of Radiation and Chemotherapy for Low-Risk HPV-related Oropharyngeal SCC: Follow-up Study
NCT02281955
Completed
The purpose of this research study is to learn about the effectiveness of using lower-intensity radiation and chemotherapy to treat human papillomavirus (HPV) associated low-risk oropharyngeal and/or unknown primary squamous cell carcinomas of the head and neck. The cure rate for this type of cancer is estimated to be high, \> 90%. The standard treatment for this cancer is 7 weeks of radiation with 3 high doses of cisplatin. Sometimes surgery is performed afterwards. This standard regimen causes... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/12/2024
Locations: University of Florida, Gainesville, Florida +4 locations
Conditions: Carcinoma, Squamous Cell, Head and Neck Neoplasms, Oropharyngeal Neoplasms
Register for Updates
Phase 1 Study of INBRX-109 in Subjects with Locally Advanced or Metastatic Solid Tumors Including Sarcomas
NCT03715933
Recruiting
This is a first-in-human, open-label, non-randomized, three-part phase 1 trial of INBRX-109, which is a recombinant humanized tetravalent antibody targeting the human death receptor 5 (DR5).
Gender:
ALL
Ages:
Between 12 years and 85 years
Trial Updated:
12/09/2024
Locations: HonorHealth Research Institute, Scottsdale, Arizona +33 locations
Conditions: Colorectal Adenocarcinoma, Ewing Sarcoma
Register for Updates
A Study of Nivolumab and Ipilimumab Combined With Chemotherapy Compared to Chemotherapy Alone in First Line NSCLC
NCT03215706
Completed
The purpose of this study is to determine whether Nivolumab, Ipilimumab combined with chemotherapy is more effective than chemotherapy by itself when treating stage IV NSCLC as the first treatment given for the disease
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/06/2024
Locations: Memorial Health Systems, Colorado Springs, Colorado +115 locations
Conditions: Non-Small Cell Lung Cancer
Register for Updates
Safety and Pharmacokinetics (PK) of Escalating Doses of Tiragolumab as a Single Agent and in Combination With Atezolizumab and/or Other Anti-Cancer Therapies in Locally Advanced or Metastatic Tumors
NCT02794571
Completed
This first-in-human open-label, multicenter, dose-escalation and expansion study is designed to evaluate the safety, tolerability, and PK of tiragolumab alone or in combination with atezolizumab and/or other anti-cancer therapies in participants with locally advanced, recurrent, or metastatic incurable tumors for whom standard therapy does not exist, has proven to be ineffective or intolerable, or is considered inappropriate, or for whom a clinical trial of an investigational agent is a recogniz... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/04/2024
Locations: Honor Health Research Institute, Scottsdale, Arizona +27 locations
Conditions: Advanced/Metastatic Tumors
Register for Updates
Combination Therapy for Patients With Untreated Metastatic Pancreatic Ductal Adenocarcinoma
NCT02754726
Completed
The purpose of this study is to find out if the study drugs nivolumab, albumin- bound paclitaxel, paricalcitol, cisplatin, and gemcitabine given together are safe and effective when combined to treat advanced pancreatic cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/02/2024
Locations: Clinical Trials Nurse Navigator, Scottsdale, Arizona
Conditions: Untreated Metastatic Pancreatic Ductal Adenocarcinoma
Register for Updates